RxDoctor Payments Data

Debra Greenfield, MD

Internal Medicine · West Hempstead, NYNPI 1558525964

Payments from drug & device makers

$2,404in general payments, 2019–2025

Across 123 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$508
  • Vivus LLC$507
  • Novo Nordisk$480
  • Currax Pharmaceuticals LLC$331
  • Lilly USA, LLC$217
  • Eisai Inc.$196
  • plus $165 from 5 others

What the payments were for

  • Food & beverage$2,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intra-sana Laboratories12$508
Vivus LLC24$507
Novo Nordisk30$480
Currax Pharmaceuticals LLC24$331
Lilly USA, LLC11$217
Eisai Inc.13$196
Bausch Health US, LLC3$56
Nalpropion Pharmaceuticals LLC3$49
Abbott1$25
Medicomp Inc1$18
Arbor Pharmaceuticals, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,404 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$44,110
Medicare patients
68
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide207$213,361
OzempicSemaglutide156$163,508
WegovySemaglutide53$72,058
RybelsusSemaglutide15$30,827
Metformin Hcl119$6,901
Naltrexone Hcl25$674
Famotidine14$408
Topiramate18$95
Levothyroxine Sodium13$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$480$266,394224 claims
Lilly USA, LLCMounjaro$217$213,361207 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in West Hempstead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →